What is Belyntic?
Belyntic operates at the intersection of artificial intelligence and immunology, specializing in the development of novel immunotherapies. The company's core asset, the T-Fender platform, is engineered to harness the patient's own immune system, specifically targeting T cell responses to combat complex pathologies. By integrating AI-driven predictive modeling, Belyntic rapidly iterates on vaccine candidates, ensuring high stability and efficacy profiles. This dual-pronged approach—combining biological innovation with computational precision—positions the firm as a high-potential player in the global biotech sector, particularly in the creation of both therapeutic and prophylactic vaccines.
How much funding has Belyntic raised?
Belyntic has raised a total of $1.5M across 1 funding round:
Angel/Seed
$1.5M
Angel/Seed (2019): $1.5M with participation from High-Tech Gründerfonds, Investitionsbank Berlin, and Till Knorr
Key Investors in Belyntic
High-Tech Gründerfonds
A prominent German venture capital firm specializing in early-stage technology and life science investments, providing both capital and strategic mentorship to high-growth startups.
Investitionsbank Berlin
The development bank of the state of Berlin, which provides essential financial support and economic promotion for innovation, startups, and sustainable urban development projects.
Till Knorr
An individual investor providing strategic backing and capital to support the early-stage development of innovative biotech ventures.
What's next for Belyntic?
Looking ahead, Belyntic is poised to leverage its recent financing to scale its T-Fender platform and expand its pipeline of vaccine candidates. The strategic roadmap involves deepening collaborative efforts with industry partners to facilitate the transition of its lead assets toward clinical trials. As the company continues to refine its AI-based design technology, the focus will shift toward optimizing manufacturing processes and securing regulatory milestones. This phase of growth is essential for Belyntic to demonstrate the clinical utility of its cellular immunity solutions, ultimately aiming to provide transformative treatment options for vulnerable patient populations worldwide.
See full Belyntic company page
